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Abstract
Background: Chronic kidney disease (CKD) is the most common cause of secondary hypertension. More than half of the
patients have uncontrolled hypertension (140/90 mmHg on three or more antihypertensive agents at optimum doses).
Renal sympathetic denervation (RSDN) has been shown to reduce blood pressure (BP) in patients with resistant
hypertension. Although patients with CKD have high sympathetic drive, all major clinical trials have excluded patients
with estimated glomerular filtration rates (eGFRs)<45 mL/min/1.73m2 for risk of contrast-induced nephropathy.
Methods: In this pilot study, carbon dioxide (CO2) was used as the sole contrast agent to carry out renal angiography and
RSDN in patients with moderate to severe CKD (eGFR 15–44 mL/min/1.73m2) and uncontrolled hypertension.
Results: Eleven patients (eight males) underwent RSDN. The median age was 57 years [interquartile range (IQR) 49–66]. The
median number of antihypertensives being taken at baseline was 4 (IQR 3–4). No statistically significant difference was
observed in serum creatinine in the serial follow-ups until at 6 months[median difference 0.25 mg/dL (IQR 0.09–0.53);
P¼0.008]. There was a non-significant reduction in median clinic BP from baseline to 6 months [14 mmHg (IQR 24–5)] and
a significant increase in daytime ambulatory systolic BP [7 mmHg (IQR 2–12); P¼0.045]. A trend towards a serial reduction
in albuminuria was observed. Procedure-related complications included a groin haematoma (n¼1) and reported flank
(n¼1) and groin pain (n¼1).
Conclusions: This pilot study shows that CO2 renal angiography can be used to perform RSDN in patients with significant
renal impairment and may lead to associated improvements in clinic BP and albuminuria.
Key words: carbon dioxide angiography, chronic kidney disease (CKD), contrast nephropathy, renal sympathetic denervation,
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Background
Hypertension is a risk factor for cardiovascular disease and
chronic kidney disease (CKD). If it remains uncontrolled it can
lead to rapid progression of CKD and is a leading cause of end-
stage renal disease (ESRD). On the other hand, CKD itself can
exacerbate hypertension, often necessitating the use of a com-
bination of antihypertensive drugs of different classes to bring
elevated blood pressure (BP) under control. Compared with peo-
ple without CKD, the prevalence of treatment-resistant hyper-
tension (TRH) is reported to be twice as high in patients with
CKD. In the 3612 Chronic Renal Insufficiency Cohort study par-
ticipants with CKD, 42% had apparent TRH [1].
Patients with CKD have a much higher risk of cardiovascular
disease when compared with patients without CKD; meta-
analyses show impaired renal function to be an independent
risk factor for cardiovascular disease [2]. Vascular calcifications
are more pronounced in CKD and may be partly responsible for
the excess cardiovascular morbidity and mortality observed in
CKD patients [3]. Moreover, improvement in BP control is known
to slow the decline of renal function in patients with CKD [4].
The pathophysiology of hypertension in CKD is multifacto-
rial, with sodium retention and excessive activation of the
renin–angiotensin system (RAS) being the most important.
Symmetric renal involvement is important for the uncontrolled
progression of the RAS because if a single kidney is affected, the
other one compensates [5]. CKD is the perfect example of sym-
metric involvement. The sympathetic nervous system is also
overactive and has been implicated to play role in the progres-
sion of CKD [6]. In ESRD, sympathetic nerve activity is substan-
tially increased and elevated noradrenaline plasma levels have
been linked with poor cardiovascular outcomes [7, 8]. Recently,
procedure-based approaches have been investigated in patients
with TRH to achieve BP control. Percutaneous catheter-based
radiofrequency ablation of afferent and efferent sympathetic
nerves of renal arteries is one such technique and is the most
widely researched to date. It is purported to address certain
interorgan crosstalk pathways that may be upregulated in non-
atherosclerotic nephrogenic hypertension [9]. Due to the risk of
contrast-induced nephropathy associated with the use of iodi-
nated contrast materials, patients with an estimated glomerular
filtration rate (eGFR)<45 mL/min/1.73 m2 have been excluded
from major trials of renal sympathetic denervation (RSDN).
Only a handful of pilot studies thus far have investigated the
use of RSDN in patients with moderate to severe eGFR (15–
44 mL/min/1.73 m2) [10–14].
Carbon dioxide (CO2) angiography is a well-recognized and
safe alternative to iodine-based contrast material in patients
with CKD or iodinated contrast agent allergy [15–17]. A negative
contrast image with digital subtraction angiography is produced
when the directly injected CO2 displaces blood intravascularly.
CO2 angiography has been shown to prevent deterioration of
renal function in patients with known renal impairment and
has been successfully used in such patients for various diagnos-
tic and therapeutic indications [10, 16–18].
In this pilot study, we examined the safety and efficacy of
RSDN performed using CO2 as the sole contrast agent in
patients with significant renal impairment (eGFR 15–45 mL/min/
1.73 m2).
Materials and methods
All patients 18–75 years of age were recruited from screening
patients attending the outpatient nephrology and specialist
hypertension clinic at Heart of England NHS Foundation Trust
in Birmingham. Patients were screened based on their outpa-
tient clinic systolic BP, number of antihypertensive medications
used and outpatient eGFR. Only patients with TRH, outpatient
clinic systolic BP140 mmHg while taking at least three antihy-
pertensive medications and an eGFR between 15 and 44 mL/
min/1.73 m2 were selected for RSDN. Patients with an
eGFR 45 mL/min/1.73 m2 or<15 mL/min/1.73 m2, diagnosis of
type 1 diabetes mellitus, substantial stenotic valvular heart dis-
ease, pregnancy or planned pregnancy during the study and a
history of myocardial infarction, unstable angina or cerebrovas-
cular accident in the previous 6 months were excluded.
At the baseline visit, clinic BP was assessed in a standardized
manner following the British Hypertension Society guidelines.
Briefly, an average of at least two systolic BPs was used to con-
firm systolic hypertension. BP was taken with patients resting
in a chair for 5 min and a 1-min interval between the end of one
measurement and the start of the next measurement. All
patients had baseline serum electrolytes, urea and creatinine,
urinary albumin:creatinine ratio (ACR) and 24-h ambulatory BP
measured. Serum creatinine was used to calculate eGFR using
the Modification of Diet in Renal Disease (MDRD) equation to
confirm that the baseline eGFR met the inclusion criteria.
Anatomical suitability for RSDN was confirmed using non-
contrast computed tomography (CT) reconstruction of renal
arteries. Baseline data recorded include basic demographics,
comorbidities and the number and names of antihypertensive
medications.
Renal angiography was performed utilizing CO2 as the sole
contrast agent to confirm the renal anatomy prior to performing
RSDN [19]. The procedure was carried out in all patients by two
interventional radiologists, both with considerable experience
in both CO2 angiography and RSDN. RSDN was performed using
either the single or multi-electrode radiofrequency Symplicity
catheter (Medtronic, Mountain View, CA, USA) in all patients as
described previously [20]. The procedure was carried out as a
day case.
All patients were followed up at 7 days and 1, 3 and 6 months
post-procedure to assess renal function and BP response and to
monitor any potential procedural complications. At each visit a
medication review, clinic BP and urinary ACR was carried out.
A repeat ambulatory BP monitoring (ABPM) was performed at
the 6-month follow-up visit to assess clinical response. There
was no a priori restriction on changes to antihypertensive medi-
cations after RSDN.
Statistical analysis was performed using SPSS Statistics 22
(IBM, Armonk, NY, USA). The Shapiro–Wilk test was applied to
test for normality of distribution of data. Median and interquar-
tile range (IQR) have been used to report the non-normally dis-
tributed parameters. Related-samples Wilcoxon signed rank
test was used to compare baseline creatinine, eGFR and clinic
and ABPM readings with follow-up readings to detect any statis-
tically significant changes. A two-sided P-value <0.05 was con-
sidered statistically significant. Written informed consent was
obtained from all patients. The study was reviewed by the local
research ethics committee (NRES Committee West Midlands,
Edgbaston) and granted approval. The study was registered
with ClinicalTrials.gov (NCT02863510).
Results
Eleven patients with CKD underwent RSDN. The baseline char-
acteristics for the patients are summarized in Table 1. There
were eight (72.7%) men and the median age was 57 years (IQR
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49–66). Seven (63.6%) patients were Caucasian, two (18.2%)
African Caribbean and two (18.2%) South Asian.
The median number of antihypertensive medications taken
by the study population at baseline was 4 (IQR 3–4). All patients
were taking a calcium channel blocker (CCB), nine (81.8%) were
taking either an angiotensin-converting enzyme (ACE) inhibitor
or an angiotensin receptor blocker and seven (63.6%) were taking
at least one diuretic (loop, thiazide/thiazide-like or potassium-
sparing). At 6 months, most patients [n¼ 9 (81.8%)] were taking
the same number of antihypertensive medications and two
patients had at least one antihypertensive medication stopped.
Table 2 summarizes the results of renal function, albuminuria
and BP parameters at the baseline and follow-up visits. The base-
line median serum creatinine was 2.26 mg/dL (IQR 1.66–3.47) with
a median eGFR of 29 mL/min/1.73 m2 (IQR 18–41). The median of
differences between serum creatinine at baseline and 6 months
post-RSDN was 0.25 mg/dL (IQR 0.09–0.53), which was statistically
significant (P¼ 0.008). The median of differences between serum
creatinine at baseline and the earlier follow-up visits were not
statistically significant. Similarly, the median of differences
between eGFR at baseline and the 6-month follow-up visit was
statistically significant with a median difference of 4 mL/min/
1.73 m2 (IQR 11 to 1); P ¼ 0.012. The median albuminuria, meas-
ured as urine ACR, of the study population showed an improving
trend (Table 2); however, the median of differences in ACR at the
baseline and follow-up visits was not statistically significant.
At baseline the median clinic BP was 170 mmHg (IQR 158–
180) systolic and 89 mmHg (IQR 74–99) diastolic. The median
clinic systolic BP was lower at 6 months but the median of the
difference, 14 mmHg (IQR 24–5), was not statistically signifi-
cant. The apparent reduction in the median clinic BP was not
accompanied by a corresponding reduction in ambulatory BP
parameters, where the median systolic BP was higher at
6 months overall and when separated into day and night (Table
2). Statistically, however, the median of the difference was only
found to be significant for daytime systolic BP, which was
7 mmHg (IQR 2–12), P ¼ 0.045. The change in all other ambula-
tory BPs was not statistically significant.
The mean total number of radiofrequency ablations deliv-
ered during the RSDN procedure was 11.3 (SD 2.4). There were
no minor atherosclerotic findings, which could have limited the
radiofrequency ablation probe contact with the true wall of the
artery, in any of the patients who underwent RSDN. Patients
with significant renal artery stenosis due to any atherosclerotic
lesions were excluded at the screening stage by CT renal angio-
gram. Procedure-related complications observed included one
patient with flank pain that was managed with simple analge-
sics, another patient with groin pain that did not require any
analgesics and another patient with a groin haematoma requir-
ing overnight admission but no intervention. Two patients pro-
gressed to end-stage renal disease requiring dialysis; one
patient commenced on peritoneal dialysis at 6 months and 10
days after the procedure and the other required haemodialysis
at 5 months and 27 days.
Discussion
This is the first reported study to perform RSDN with the sole
use of CO2 as a contrast agent. This pilot study shows that CO2
renal angiography can be used safely to perform RSDN in
patients with significant renal impairment where there is a risk
of contrast-induced nephropathy commonly associated with
iodinated contrast agents. We showed that at 7 days after the
procedure there was no significant change in the median serum
creatinine and eGFR. There was no significant improvement in
BP control, but there was a trend towards an improvement in
albuminuria at 6 months.
The primary aim of this study was whether the use of iodi-
nated contrast agents could be avoided in patients with signif-
icant renal impairment and uncontrolled hypertension to
successfully perform RSDN using CO2 angiography. CO2
angiography is not completely risk free; however, the adverse
events associated with CO2 angiography are uncommon and
are usually limited to the organs being injected [21]. In particu-
lar, a vapour lock phenomena can occur where the large doses
of CO2 can cause obstruction to blood flow and hence ischae-
mia downstream if unresolved. Contamination of CO2 with
room air can result in air embolus. Neurotoxicity, pain, nau-
sea, vomiting and an urge to defecate are among the other
possible complications. The risk of these rare complications
can be reduced through understanding the unique properties
of CO2 and making sure appropriate precautions are observed
when preparing and administering it [21, 22]. No patients in
this study cohort suffered any adverse events that could be
attributable to CO2 angiography and the only observed adverse
events were secondary to puncture site complications, which
are common to any percutaneous angiographic procedure. CO2
with digital subtraction angiography allowed adequate place-
ment of the RSDN catheter to allow radiofrequency ablation,
which was confirmed by the impedance drops observed for
each ablation.
It is well known that the risk of developing contrast-induced
nephropathy is associated with the volume of contrast used.
CO2 renal artery angiography has been used to reduce but not
completely eliminate the amount of iodinated contrast given
when carrying out intravascular procedures in individuals with
significant renal function impairment [10]. In our study, the use
of iodinated contrast agents has been wholly replaced by CO2,
completely negating the risk of developing contrast-induced
nephropathy. There are no reported studies comparing the
safety of CO2 versus radio-iodine contrast with pre-procedural
hydration in patients undergoing RSDN. However, a recent
Table 1. Baseline characteristics
Characteristics Results
Age (years), median (IQR) 57.0 (49.0–66.0)
Gender, n (%)
Male 8 (72.7)
Female 3 (27.3)
Ethnicity, n (%)
Caucasian 7 (63.6)
Afro-Caribbean 2 (18.2)
Asian 2 (18.2)
BMI (kg/m2), median (IQR) 32.8 (25.7–38.7)
Comorbidities, n (%)
Type 2 diabetes mellitus 5 (45.5)
Cerebrovascular disease 2 (18.2)
Antihypertensive medication, n (%)
ACE inhibitor 4 (36.4)
Angiotensin receptor blocker 5 (45.5)
Aldosterone antagonist 1 (9.1)
a-adrenergic blocker 5 (45.5)
b-blocker 4 (36.4)
Calcium channel blocker 11 (100)
Loop diuretic 5 (45.5)
Thiazide/thiazide-like diuretic 2 (18.2)
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meta-analysis comparing the incidence of acute kidney injury
with CO2 versus iodinated contrast media reported that CO2 use
is associated with a modestly reduced rate of AKI despite the
patients with iodinated contrast media being optimized with
pre-hydration [23]. Furthermore, a recent randomized con-
trolled trial of prophylactic hydration to protect renal function
from intravascular iodinated contrast material in patients at
high risk of contrast-induced nephropathy found no prophy-
laxis to be non-inferior and cost saving in preventing contrast-
induced nephropathy compared with intravenous hydration
[24]. Patients with CKD are at a higher risk of developing con-
trast nephropathy and any measures that help reduce the risk
of contrast-induced nephropathy should be considered for
patients undergoing interventional procedures.
Unlike other studies of RSDN [25, 26], only a modest reduc-
tion in clinic systolic BP was observed 6 months after RSDN.
Conversely, ambulatory systolic BP readings were higher at
6 months. The most likely explanation for this observed rise in
ambulatory systolic BP could be progression of CKD and the
consequent sodium and water retention. In nine (82%) of the
patients serum creatinine was higher, and accordingly a lower
eGFR, at 6 months after RSDN when compared with baseline
values.
The median serum creatinine at 7 days after RSDN showed
no significant decline and, if anything, a trend towards
improved creatinine. However, by 6 months the decline in kid-
ney function was statistically significant, suggesting a contin-
ued progression of CKD. Given the small number of patients in
the study, a detailed analysis of whether RSDN affected the rate
of decline in kidney function was not performed. A recent study
in 46 patients with CKD (baseline eGFR 60 mL/min/1.73m2) has
provided some evidence that RSDN can slow further deteriora-
tion of renal function irrespective of BP-lowering effects [14].
These results build on similar findings reported by others [13,
27].
There is some evidence to suggest that RSDN may have a
beneficial effect in reducing urinary albumin excretion that may
be unrelated to improvement in BP control [27]. In this study, a
non-significant trend towards improved urinary excretion
appeared at 4 weeks post-procedure and was maintained at
subsequent follow-ups until 6 months.
Conclusions
This is the first study of RSDN in patients with moderate to
severe CKD that has avoided the use of traditional iodinated
contrast media altogether by replacing it with CO2 angiography.
However, this was a pilot single-arm study with no sham com-
parator and was not powered to detect a meaningful reduction
in clinic or ambulatory BPs. The results have shown that there
were no adverse procedural events associated with CO2 angiog-
raphy and any future trials of RSDN should not exclude patients
with moderate to severe CKD on the basis of the risk of
contrast-induced nephropathy associated with the conven-
tional methods. Further research, with a larger study popula-
tion, is needed to investigate whether RSDN can achieve
substantial reductions in BP and albuminuria and have any
effect on the rate of decline of CKD.
Funding
This work has been supported by an unrestricted research
grant from Medtronic (to J.S.F. and I.D.) and unrestricted
educational grants from Medtronic and Biosensors (to R.W.).
Conflict of interest statement
None declared.
References
1. Muntner P, Anderson A, Charleston J et al. Hypertension
awareness, treatment, and control in adults with CKD:
results from the chronic renal insufficiency cohort (CRIC)
study. Am J Kidney Dis 2010; 55: 441–451
2. Mahmoodi BK, Matsushita K, Woodward M et al.
Associations of kidney disease measures with mortality and
end-stage renal disease in individuals with and without
hypertension: a meta-analysis. Lancet 2012; 380: 1649–1661
3. Sag AA, Covic A, London G et al. Clinical imaging of vascular
disease in chronic kidney disease. Int Urol Nephrol 2016; 48:
827–837
4. Bakris GL, Williams M, Dworkin L et al. Preserving renal func-
tion in adults with hypertension and diabetes: a consensus
approach. Am J Kidney Dis 2000; 36: 646–661
5. Sag AA, Sos TA, Benli C et al. Atherosclerotic renal artery
stenosis in the post-CORAL era part 2: new directions in
transcatheter nephron salvage following flawed revasculari-
zation trials. J Am Soc Hypertens 2016; 10: 368–377
6. Grassi G, Quarti-Trevano F, Seravalle G et al. Early sympa-
thetic activation in the initial clinical stages of chronic renal
failure. Hypertension 2011; 57: 846–851
Table 2. Study parameters at baseline and serial follow-up
Parameter Baseline (n¼ 11) Week 1 (n¼ 11) Week 4 (n¼ 11) Week 12 (n¼ 10) Week 26 (n¼ 11)
Creatinine (mg/dL) 2.26 (1.66–3.47) 2.02 (1.91–3.45) 2.27 (1.75–3.35) 2.21 (1.75–4.07) 2.24 (1.71–3.81)
eGFR (mL/min/1.73m2) 29 (18–41) 33 (19–36) 29 (20–38) 28 (16–38) 25 (17–34)
Urine ACR (mg/mmol) 203 (63–412) 231 (55–283) 136 (23–386) 146 (15–382) 137 (6–370)
Clinic SBP (mmHg) 170 (158–180) 169 (158–175) 157 (135–170) 159 (152–177) 164 (149–174)
Clinic DBP (mmHg) 89 (75–95) 87 (78–87) 83 (74–91) 86 (71–103) 86 (74–94)
24-h ambulatory SBP (mmHg) 155 (149–161) 161 (149–168)
24-h ambulatory DBP (mmHg) 86 (73–94) 86 (84–101)
Day ambulatory SBP (mmHg) 159 (149–164) 163 (152–167)
Day ambulatory DBP (mmHg) 89 (75–95) 88 (84–100)
Night ambulatory SBP (mmHg) 147 (141–163) 155 (144–169)
Night ambulatory DBP (mmHg) 82 (73–86) 83 (74–90)
All values are given as median (IQR). Conversion factor for creatinine in mg/dL to mmol/L,88.4. DBP, dialstolic blood pressure; SBP, systolic blood pressure.
Renal denervation in chronic kidney disease | 781
Downloaded from https://academic.oup.com/ckj/article-abstract/10/6/778/4096802
by guest
on 15 December 2017
7. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephr-
ine predicts survival and incident cardiovascular events in
patients with end-stage renal disease. Circulation 2002; 105:
1354–1359
8. Schlaich MP, Socratous F, Hennebry S et al. Sympathetic acti-
vation in chronic renal failure. J Am Soc Nephrol 2009; 20:
933–939
9. Sag A, Sal O, Kilic Y et al. The concept of crosstalk-directed
embryological target mining and its application to essential
hypertension treatment failures. J Clin Hypertens 2017; 19:
530–533
10. Hering D, Mahfoud F, Walton AS et al. Renal denervation in
moderate to severe CKD. J Am Soc Nephrol 2012; 23: 1250–1257
11. Kiuchi MG, Maia GL, de Queiroz Carreira MA et al. Effects of
renal denervation with a standard irrigated cardiac ablation
catheter on blood pressure and renal function in patients
with chronic kidney disease and resistant hypertension. Eur
Heart J 2013; 34: 2114–2121
12. Kiuchi MG, Chen S, Andrea BR et al. Renal sympathetic
denervation in patients with hypertension and chronic kid-
ney disease: does improvement in renal function follow
blood pressure control? J Clin Hypertens 2014; 16: 794–800
13. Ott C, Mahfoud F, Schmid A et al. The effect of renal denerva-
tion in moderate treatment-resistant hypertension with
confirmed medication adherence. J Hypertens 2016; 34:
2475–2479
14. Hering D, Marusic P, Duval J et al. Effect of renal denervation
on kidney function in patients with chronic kidney disease.
Int J Cardiol 2017; 232: 93–97
15. Moos JM, Ham SW, Han SM et al. Safety of carbon dioxide dig-
ital subtraction angiography. Arch Surg 2011; 146: 1428–1432
16. Kawasaki D, Fujii K, Fukunaga M et al. Safety and efficacy of
carbon dioxide and intravascular ultrasound-guided stent-
ing for renal artery stenosis in patients with chronic renal
insufficiency. Angiology 2015; 66: 231–236
17. Fujihara M, Kawasaki D, Shintani Y et al. Endovascular ther-
apy by CO2 angiography to prevent contrast-induced nephr-
opathy in patients with chronic kidney disease: a
prospective multicenter trial of CO2 angiography registry.
Catheter Cardiovasc Interv 2015; 85: 870–877
18. Schreier DZ, Weaver FA, Frankhouse J et al. A prospective
study of carbon dioxide—digital subtraction vs standard
contrast arteriography in the evaluation of the renal arteries.
Arch Surg 1996; 131: 503–508
19. Renton M, Hameed MA, Dasgupta I et al. The use of carbon
dioxide angiography for renal sympathetic denervation:
a technical report. Br J Radiol 2016; 89: 20160311
20. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal
sympathetic denervation for resistant hypertension: a mul-
ticentre safety and proof-of-principle cohort study. Lancet
2009; 373: 1275–1281
21. Caridi JG, Hawkins IF Jr. CO2 digital subtraction angiography:
potential complications and their prevention. J Vasc Interv
Radiol 1997; 8: 383–391
22. Hawkins IF, Caridi JG. Carbon dioxide (CO2) digital subtrac-
tion angiography: 26-year experience at the University of
Florida. Eur Radiol 1998; 8: 391–402
23. Ghumman SS, Weinerman J, Khan A et al. Contrast induced-
acute kidney injury following peripheral angiography with
carbon dioxide versus iodinated contrast media: a meta-
analysis and systematic review of current literature. Catheter
Cardio Inte 2017. doi:10.1002/ccd.27051
24. Nijssen EC, Rennenberg RJ, Nelemans PJ et al. Prophylactic
hydration to protect renal function from intravascular
iodinated contrast material in patients at high risk of
contrast-induced nephropathy (AMACING): a prospective,
randomised, phase 3, controlled, open-label, non-inferiority
trial. Lancet 2017; 389: 1312–1322
25. Bhatt DL, Kandzari DE, O’Neill WW et al. A controlled trial of
renal denervation for resistant hypertension. N Engl J Med
2014; 370: 1393–1401
26. Azizi M, Sapoval M, Gosse P et al. Optimum and stepped care
standardised antihypertensive treatment with or without renal
denervation for resistant hypertension (DENERHTN): a multi-
centre, open-label, randomised controlled trial. Lancet 2015; 385:
1957–1965
27. Kiuchi MG, Graciano ML, Carreira MA et al. Long-term effects
of renal sympathetic denervation on hypertensive patients
with mild to moderate chronic kidney disease. J Clin
Hypertens 2016;18:190–196
782 | M.A. Hameed et al.
Downloaded from https://academic.oup.com/ckj/article-abstract/10/6/778/4096802
by guest
on 15 December 2017
